Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Universal Health Services (UHS) Hits 52-Week Low on Dull Q3
by Zacks Equity Research
Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.
Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.
Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View
by Zacks Equity Research
Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
What's in Store for Madrigal (MDGL) This Earnings Season?
by Zacks Equity Research
Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.
What's in Store for Catalyst (CPRX) This Earnings Season?
by Zacks Equity Research
Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.
Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base
by Zacks Equity Research
Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.
Envision Healthcare Continues to Expand Physician Services
by Zacks Equity Research
Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.
Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now
by Zacks Equity Research
The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.
STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat
by Zacks Equity Research
STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.
Here's Why You Should Invest in Orthofix International Now
by Zacks Equity Research
Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.
Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?
by Zacks Equity Research
AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.
Omnicell (OMCL) Gains on Product Launches, Global Expansion
by Zacks Equity Research
The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.
Align Technology (ALGN) Prospects Bright, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strong InvisAlign sales amid macroeconomic headwinds.
PetMed Express Optimistic on New Orders Amid Stiff Rivalry
by Zacks Equity Research
PetMed is striving to implement several strategies to revitalize its top line. Yet a highly competitive market poses threats.
Anthem to Boost Medicare in Florida With HealthSun Buyout
by Zacks Equity Research
Anthem's (ANTM) inorganic growth continues to boost its top line. It strategically deploys capital in acquisitions to position its Medicare business for further growth.
Medtronic Advances in Pain Therapy With U.S. Intellis Launch
by Zacks Equity Research
We look forward to a solid customer adoption of Medtronic's (MDT) Intellis platform, considering the vast and expanding market for chronic pain management.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
The market is upbeat about Abbott (ABT) acquiring the national reimbursement for FreeStyleLibre glucose monitoring system in the United Kingdom. Several product launches also add value.
Amedisys or Chemed: Which is a Better Investment Choice?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Amedisys (AMED) and Chemed (CHE).
Why Should Investors Add Amedisys (AMED) to Their Portfolio?
by Zacks Equity Research
Amedisys (AMED) rides high on solid prospects with new opportunities within home health and hospice services segments.
Here's Why You Should Invest in IDEXX Laboratories (IDXX) Now
by Zacks Equity Research
IDEXX Laboratories (IDXX) continues to boost investor's confidence with strong companion animal business along with balanced growth across all segments.
Why is Edwards Lifesciences (EW) a Strong Buy Stock Now?
by Zacks Equity Research
Several recent FDA product-approvals boost investors' trust in Edwards Lifesciences' (EW) stock.
Here's Why You Should Add Chemed (CHE) to Your Portfolio
by Zacks Equity Research
Chemed (CHE) bolsters investor's confidence with continued strength in Roto-Rooter business.
Here's Why You Should Bet on BioTelemetry (BEAT) Stock Now
by Zacks Equity Research
BioTelemetry's (BEAT) consistent efforts in product innovation through research and development buoy optimism. Also, the recent acquisition instills confidence in investors.